RBC Capital Markets launched its coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating on Tuesday, citing the potential of its lead drug KT-621, targeted at inflammatory conditions such as atopic dermatitis, commonly known as eczema. RBC analyst Brian Abrahams ...